For the second quarter of 2026, analysts expect STAAR Surgical to report consensus revenue of $108.4 million and EPS of $0.06, with the current stock price of $38.45 trading significantly below the average analyst price target of $52.14. Investors are primarily focused on ICL sales growth in China, which remains the company’s largest and most critical market for geographic expansion.
Recent performance has been bolstered by strong demand for the EVO ICL lens, though macroeconomic headwinds in Asian markets have historically created volatility. Management's updated full-year 2026 guidance will be essential to confirming whether the company can maintain its double-digit growth trajectory in the refractive surgery space.